Thyme Care secured $97 million in a Series D funding round led by prominent investors including CVS Health Ventures, Foresite Capital, Morgan Health, and Humana, bringing total raised to $275 million. The funding will support expansion of value-based cancer care offerings aimed at improving patient outcomes while focusing on cost-effectiveness. This capital injection signals growing investor confidence in innovative cancer care delivery models.